|Trade names||Rifater, Trifazid, others|
|AHFS/Drugs.com||FDA Professional Drug Information|
Rifampicin/isoniazid/pyrazinamide, also known as rifampin/isoniazid/pyrazinamide, is a medication used to treat tuberculosis. It is a fixed dose combination of rifampicin, isoniazid, and pyrazinamide. It is used either by itself or along with other antituberculosis medication. It is taken by mouth.
Side effects are those of the underlying medications. These may include poor coordination, loss of appetite, nausea, joint pain, feeling tired, and numbness. Severe side effects include liver problems. Use in those under the age of 15 may not be appropriate. It is unclear if use in pregnancy is safe for the baby.
Rifampicin/isoniazid/pyrazinamide was approved for medical use in the United States in 1994. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about 3.93 USD a month. In the United Kingdom a month of treatment costs the NHS about 39.51 pounds.
The purpose of the fixed dose combination is to make it easier for people to take their medication; but also to ensure that if people forget to take one or two of their drugs, they do not then develop resistance to the remaining drugs.
Society and culture
It is manufactured by Aventis.
- WHO Model Formulary 2008 (PDF). World Health Organization. 2009. p. 143. ISBN 9789241547659. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- "Rifater Side Effects in Detail - Drugs.com". www.drugs.com. Archived from the original on 21 December 2016. Retrieved 18 December 2016.
- "Rifater - FDA prescribing information, side effects and uses". www.drugs.com. October 2016. Archived from the original on 21 December 2016. Retrieved 18 December 2016.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016.
- "Rifampicin + Isoniazid + Pyrazinamide". International Drug Price Indicator Guide. Retrieved 8 December 2016.
- British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 403. ISBN 9780857111562.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|